Huriem Tablet 25/5 mg (Empagliflozin, Linagliptin)
Empagliflozin Micronized 25mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
MFDS item code 202402466 · Approved 2024.10.21
Improvement of blood glucose control in patients with type 2 diabetes
This medication is used to assist in the control of blood sugar for patients with type 2 diabetes. It is particularly suited for use when taking Empagliflozin and Linagliptin together, helping to manage blood sugar effectively in conjunction with dietary and exercise therapies. By maintaining stable blood sugar levels, it aids in the treatment of diabetes.
The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. If additional glycemic control is needed and empagliflozin 10 mg/linagliptin 5 mg is tolerated, the dose of this medicine may be increased to 25/5 mg once daily. Patients switching to this medicine from concomitant therapy with empagliflozin and linagliptin should receive their existing doses. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of your next dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose in one day. Special populations Patients with renal impairment This medicine is not recommended for improving glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is required in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. Older adults No dose adjustment based on age is required. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication contains Empagliflozin and Linagliptin, and is used in the treatment of diabetes. First, individuals who are allergic to Empagliflozin, Linagliptin, or any other ingredients in this medication should not take it. Additionally, it should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Patients with significantly decreased kidney function, specifically those with a glomerular filtration rate below 30ml/min/1.73m², those with end-stage kidney disease, or those undergoing dialysis should not take this medication. In cases of mildly impaired kidney function, regular kidney function testing before and during treatment is important. Patients with mild to moderate heart failure should use this medication cautiously, and it is not recommended for patients with severe heart failure. Linagliptin may cause acute pancreatitis, so if symptoms such as severe abdominal pain occur, discontinue the medication immediately and consult a physician. Additionally, a rare but serious skin condition called bullous pemphigoid may occur, so if blisters or lesions appear on the skin, inform a doctor right away. The most common side effect during the use of this medication is urinary tract infection, which may occur more frequently in women. There is a risk of hypoglycemia when taken with other hypoglycemic agents such as insulin or sulfonylureas, so caution is needed. Decreased fluid volume or symptoms of dehydration may occur, especially in elderly patients or those with low blood pressure, so fluid status should be monitored closely. This medication can increase the risk of genital fungal infections; if related symptoms arise, appropriate treatment should be sought. Women who are pregnant or nursing are advised to avoid this medication, and should consult a physician if necessary. Safety and efficacy in children under 18 years have not been established, hence it is not recommended for this age group. In case of overdose, consult with medical personnel immediately, as there is no specific antidote, and treatment should be appropriate to the patient's condition. Lastly, this medication should be kept out of reach of children and stored in its original packaging.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should maintain room temperature between 1 degree and 30 degrees. This will help preserve the effectiveness of the medication.
Light pink, triangular, film-coated tablet with flat sides and sharp edges
Bottle - 30 tablets/bottle, PTP - 30 tablets/box [(10 tablets/PTP X 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin Micronized 25mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Empagliflozin Micronized 10mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.